EYPT News and Press, EyePoint Pharmaceuticals Inc. From 07/27/23

Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is well tolerated with no reported drug-related ocular or systemic SAEs Patient demographics demonstrate the Phase 2 DAVIO 2 population has a better baseline BCVA and decreased CST compared to the Phase 1...

WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:3...

2023-07-18 17:26:50 ET Gainers: Ribbon Communications  ( NASDAQ: RBBN ) +7% . Terns Pharmaceuticals ( TERN ) +3% . Arrival ( ARVL ) +3% . EyePoint Pharmaceuticals ( EYPT ) +3% . Lyra Therapeutics  ( LYRA ) +3% . ...

2023-07-10 07:46:31 ET EyePoint ( NASDAQ: EYPT ) has appointed Jay S. Duker, M.D. as Chief Executive Officer (CEO). Duker has transitioned from his most recent role as Chief Operating Officer (COO) and President and has also been appointed to the board of the com...

– Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy S. Lurker Transitions to Executive Vice Chair of the Board of Directors Pursuant to Long Term Succession Plan – WAT...

2023-06-13 17:41:09 ET Gainers: Inventiva ( IVA ) +42% . NOVONIX  ( NVX ) +5% . EyePoint Pharmaceuticals ( EYPT ) +5% . 908 Devices  ( MASS ) +5% . Vera Therapeutics ( VERA ) +5% . Losers: Microvision ( MVIS ...

– Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target – – Topline PAVIA data anticipated in 2Q 2024 – WATERTOWN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, I...

WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that George Elston, Chief Financial Officer of EyePoint...

2023-05-30 08:00:48 ET Summary EyePoint is a $200m market cap biotech focused on eye disease. The company's long-acting Durasert technology has been supporting its commercial product, YUTIQ, which earned $28m of revenues in FY22. EyePoint recently announced however that it had...

2023-05-18 10:52:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alimera Sciences (NASDAQ: ALIM ) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (NASDAQ: EYPT ). That agreement...